Kaopectate Prop 65
This article was originally published in The Tan Sheet
San Francisco County Judge approves settlement between Pfizer, Attorney General Bill Lockyer in Prop 65 lawsuit regarding Kaopectateanti-diarrheal. Pfizer, which obtained the drug after acquiring Pharmacia, agrees to reformulate Kaopectate liquid with 80% less lead; caplets have not yet been reformulated. "The faster and more extensively Pharmacia removes lead from Kaopectate, the less it will pay in civil penalties," AG's office states June 26. Center for Environmental Health filed suit in 2001 (1"The Tan Sheet" March 26, 2001, p. 21). State AG joined in November 2001...
You may also be interested in...
Requiring a special California Proposition 65 pregnancy warning on OTC nicotine-containing smoking cessation patches and gums would conflict with FDA requirements, a San Francisco state court judge has ruled.
Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker